Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 247-252 , December 2008

Financial Consequences of Improved Treatments for Colorectal Cancer

  • Yu-Ning Wong, MD, MSCE

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Yu-Ning Wong, MD, MSCE, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111

References 

  1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–2351
  2. The NCCN Colon Cancer Clinical Practice Guidelines in Oncology (Version 1.2008). [DONE]© 2008 National Comprehensive Cancer Network, Inc. http://www.nccn.orgAccessed April 30, 2008
  3. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520
  4. Benson AB. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res. 2007;13(22):6913s–6920s
  5. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage ii colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395–3407
  6. Colorectal Cancer Cancer Version 2.2008, in Practice Guidelines in Oncology. National Comprehensive Cancer Network. 2007;
  7. Hoffman JM, Shah ND, Vermeulen LC, et al. Projecting future drug expenditures—2007. Am J Health Syst Pharm. 2007;64(3):298–314
  8. Medicare Part B Drugs and Oncology, Statement of Mark E. Miller, PhD, in Subcommittee on Health, House Ways and Means. Washington DC, 2006
  9. Meropol NJ, Schulman KA. Perspectives on the cost of cancer care. J Clin Oncol. 2007;25(2):169–170
  10. Pauly MV. Is high and growing spending on cancer treatment and prevention harmful to the United States economy?. J Clin Oncol. 2007;25(2):171–174
  11. Ramsey SD. How should we pay the piper when he's calling the tune? (On the long-term affordability of cancer care in the United States). J Clin Oncol. 2007;25(2):175–179
  12. Banthin JS, Bernard DM. Changes in financial burdens for health care: national estimates for the population younger than 65 years, 1996 to 2003. JAMA. 2006;296(22):2712–2719
  13. National Survey of Households Affected by Cancer: The USA Today/Kaiser Family Foundation/Harvard School of Public Health: Menlo Park, CA, 2006
  14. Banthin J, Bernard D. Out-of-pocket expenditures on health care and insurance premiums among the elderly population, 2003, in medical expenditures panel survey statistical brief #122. Washington, DC: Agency for Health Care Research and Quality; 2006;
  15. Himmelstein DU, Warren E, Thorne D, et al: MarketWatch: illness and injury as contributors to bankruptcy. Health Aff 2005:hlthaff.w5.63
  16. www.medicare.govaccessed 4/22/2008
  17. Kaa K. Medicare challenges and solutions—reimbursement issues in treating the patient with colorectal cancer. J Manag Care Pharm. 2007;13(suppl 6C):S19–S26
  18. Friedman JY, Curtis LH, Hammill BG, et al. The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?. Cancer. 2007;110(10):2304–2312
  19. Mays JB, Neuman MT, Cubanski J, et al. Estimates of Medicare beneficiaries' out of pocket drug spending in 2006 modeling the impact of MMMA, in The Medicare RX Drug Law. Menlo Park CA: The Henry J. Kaiser Family Foundation; 2004;
  20. Gellad WF, Huskamp HA, Phillips KA, et al. How The new Medicare drug benefit could affect vulnerable populations. Health Aff. 2006;25(1):248–255
  21. Schrag D, Hanger M. Medical oncologists' views on communicating with patients about chemotherapy costs: a pilot survey. J Clin Oncol. 2007;25(2):233–237
  22. Piette JD, Heisler M, Wagner TH. Cost-related medication underuse: do patients with chronic illnesses tell their doctors?. Arch Intern Med. 2004;164(16):1749–1755
  23. Kasiske BL, Cohen D, Lucey MR, et al. Payment for immunosuppression after organ transplantation (American Society of Transplantation). JAMA. 2000;283(18):2445–2450
  24. Hsu J, Price M, Huang J, et al. Unintended Consequences of caps on Medicare drug benefits. N Engl J Med. 2006;354(22):2349–2359
  25. Goldman DP, Joyce GF, Lawless G, et al. Benefit design and specialty drug use. Health Aff. 2006;25(5):1319–1331
  26. Bowman J, Rousseau A, Silk D, et al. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Aff. 2006;25(5):1240–1248
  27. Robinson JC. Insurers' Strategies For Managing The Use And Cost Of Biopharmaceuticals. Health Aff. 2006;25(5):1205–1217

PII: S1043-1489(08)00060-2

doi: 10.1053/j.scrs.2008.09.010

Seminars in Colon & Rectal Surgery
Volume 19, Issue 4 , Pages 247-252 , December 2008

Article Tools